Formulation Development
Lumen Bioscience Awarded $16.2 Million in DoD Funding to Advance LMN-201 Through Late-Stage Trials
Lumen Bioscience recently announced it was awarded $16.2 million by the US Department of Defense to advance LMN-201 through late-stage trials. LMN-201 is an investigational,…
Elevar Therapeutics & Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement
Elevar Therapeutics, Inc. and Jiangsu Hengrui Pharmaceuticals Co., Ltd. recently announced a global licensing agreement that grants Elevar rights to commercialize and develop Hengrui Pharma’s anti-PD-1 antibody camrelizumab in combination with….
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase 2b Clinical Study
ABVC BioPharma, Inc. recently announced an update on the company's 8-week long ADHD Phase 2b clinical study taking place at the University of California San…
GRI Bio Announces Partnership With the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
GRI Bio, Inc. recently announced it has entered into a collaboration with the UK consortia, National Institute for Health and Care Research Respiratory Translational Research…
Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO
Quotient Sciences recently announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective October 16, 2023. Thierry succeeds Mark Egerton who….
Terns Pharmaceuticals Announces Global Phase 1 Clinical Trial Design of TERN-701 for the Treatment of Chronic Myeloid Leukemia
Terns Pharmaceuticals, Inc. recently announced the US FDA’s clearance of its Investigational New Drug application and the design of the CARDINAL Trial, Terns’ global Phase…
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy Designation for Severe Sickle Cell Disease Treatment
Editas Medicine, Inc. recently announced the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to EDIT-301, an investigational, gene-editing medicine for the treatment of…
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO
Daré to receive $1.8-million payment; eligible for additional potential milestone payments of up to $180 million and tiered double-digit royalties based on net sales…..
Silo Pharma’s Peptide Shows Positive Results Against Rheumatoid Arthritis
Silo Pharma, Inc. recently announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human…
WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects
This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….
Nemera Extends Manufacturing Capabilities in North America
With a newly acquired space in Vernon Hills, IL, Nemera opens a third location in the United States, in addition to the manufacturing facility in Buffalo Grove and Innovation center in Chicago….
eXmoor Completes Expansion Into Full-Service Cell & Gene Therapy CDMO Partner With Opening of GMP Facilities
eXmoor pharma recently launched its new Cell and Gene Therapy Centre GMP facility, to support the simultaneous production of multiple therapies for clinical trials. The…
Ashland Showcases New Bioresorbable Polymers Technology Platform, Pharmaceutical Products & Solutions
Ashland is showcasing its recently launched bioresorbable polymers technology platform and two new life sciences products during upcoming tradeshows, including CPHI Barcelona, October 24-26, in…
Conduit Pharmaceuticals Partners With ClinConnect on Cocrystal Development Program
Collaboration underscores Conduit’s mission to advance promising treatments by developing assets that have already completed Phase 1 trials….
Veranova Announces Appointment of New Advisory Board
Veranova recently announced the appointment of a new advisory board that will provide expert scientific and strategic guidance on the company’s journey to create the leading provider of….
Olema Oncology Announces Expansion of Collaboration Agreement With Novartis
Olema Pharmaceuticals, Inc. recently announced an amendment to its existing clinical collaboration and supply agreement with Novartis Institutes for BioMedical Research, Inc. to increase the size of….
BioXcel Therapeutics Reports Positive Overall Survival Results From Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients With Small Cell Neuroendocrine Prostate Cancer
BioXcel Therapeutics, Inc. recently announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the company's investigational oral innate immune activator, in…
AviadoBio Announces Initiation of Phase 1/2 Clinical Trial Evaluating AVB-101 in People With Frontotemporal Dementia With GRN Mutations
AviadoBio recently announced it has initiated the Phase 1/2 ASPIRE-FTD clinical study of its investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with…
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial for the Treatment of Post-Bariatric Hypoglycemia
MBX Biosciences, Inc. recently announced the first healthy adult participant has been dosed in its Phase 1/2 clinical trial of MBX 1416, the company’s long-acting…
Salubris Biotherapeutics Presents Positive 6-Month Data From Phase 1b Clinical Trial of JK07
Salubris Biotherapeutics, Inc. recently announced positive updated results from the completed Phase 1b study of JK07 in patients with HFrEF. The data were presented in…
